Wall Street Analysts Are Mostly Positive on BioMarin

Earnings trends

BioMarin Pharmaceutical’s net income and EPS for the first nine months of this year amounted to -$73.6 million and -$0.42, respectively, compared to -$65.7 million and -$0.38 in the same period the prior year.

In the third quarter, BioMarin Pharmaceutical reported net income and EPS of -$12.6 million and -$0.07, respectively, compared to -$12.5 million and -$0.07 in the third quarter of 2017. BioMarin Pharmaceutical’s EPS in the third quarter of this year remained flat compared to the third quarter of 2017.

Wall Street Analysts Are Mostly Positive on BioMarin

Stock performance

On November 27, BioMarin Pharmaceutical stock closed at $96.37, which is 3% growth from its prior week close of $93.78 on November 23. BioMarin Pharmaceutical’s stock grew from $89.17 on December 29, 2017, to close at $96.37 on November 27, reflecting ~8% YTD growth.

Analysts’ recommendations

Of the 24 analysts tracking BioMarin Pharmaceutical in November, nine of them recommended a “strong buy,” while 11 analysts recommended a “buy.” Four analysts recommended a “hold” for the stock.

On November 29, BioMarin Pharmaceutical had a consensus 12-month target price of $121.67, which represents a ~23.39% return on investment over the next 12 months.

Peers’ rating

In November 2018, of 18 analysts tracking Alexion Pharmaceuticals (ALXN) ~89% of them recommended “buys” while among the 24 analysts tracking Vertex Pharmaceuticals (VRTX), ~88% of them recommended “buys.” Of the 23 analysts tracking Sarepta Therapeutics (SRPT) in November 2018, ~96% of them recommended “buys.”

On November 29, Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Sarepta Therapeutics had consensus 12-month target prices of $163.29, $201.36 and $195.43, respectively, which represents a ~32.93%, ~12.88%, and ~52.33% return on investment over the next 12 months.